Announcements
- Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
- Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
- Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Key statistics
On Friday, Cingulate Inc (CING:NAQ) closed at 0.3371, 18.70% above the 52 week low of 0.284 set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.328 |
---|---|
High | 0.3474 |
Low | 0.31 |
Bid | 0.3112 |
Offer | 0.35 |
Previous close | 0.32 |
Average volume | 1.22m |
---|---|
Shares outstanding | 7.35m |
Free float | 6.07m |
P/E (TTM) | -- |
Market cap | 2.48m USD |
EPS (TTM) | -22.66 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:59 BST.
More ▼